Recursion jumps after solid Q4 beat

Recursion Pharmaceuticals (RXRX) stock surged after the company significantly beat Street forecasts with its Q4 2025 results.

Recursion Pharmaceuticals Shares Rise After 4Q Revenue Increase

Recursion Pharmaceuticals shares were 11% higher, at $3.90, after the company reported fourth-quarter revenue that was higher than last year, and a loss that was narrower than last year's.

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological ...
Blockonomi

Cathie Wood ARK ETF Buys Recursion Pharmaceuticals and CRISPR Therapeutics Shares

Cathie Wood's ARK Invest bought Recursion Pharmaceuticals and CRISPR Therapeutics while selling PagerDuty, Teradyne, and Salesforce on8, 2026.
Visual Studio Magazine

Decision Tree Regression from Scratch Without Pointers or Recursion Using C#

Dr. James McCaffrey presents a complete end-to-end demonstration of decision tree regression from scratch using the C# language. The goal of decision tree regression is to predict a single numeric ...
BBC

Designing, creating and refining algorithms - OCR Trace tables

At each step, the programmer is able to see if, and how, a variable is affected. Trace tables are extremely useful because they enable a programmer to compare what the value of each variable should be ...